BusinessMyriad Genetics and BeiGene Sign Agreement to Develop Companion Diagnostics for Use with BeiGene’s Novel PARP Inhibitor, BGB-290By Nasdaq OMXApr 6, 2017, 11:05 AM UTC
BusinessPivotal Study Results for Myriad’s myPath® Melanoma Test Highlighted In Two Additional Scientific PublicationsBy Nasdaq OMXApr 5, 2017, 11:05 AM UTC
BusinessSaint Jean Carbon Provides Update on Anode Material OrderBy Nasdaq OMXMar 20, 2017, 11:47 PM UTC
BusinessOHIO WESLEYAN TO BEGIN CONFERRING BACHELOR OF SCIENCE DEGREESBy Nasdaq OMXMar 16, 2017, 5:12 PM UTC
BusinessMyriad Genetics Launches the EndoPredict® Test in the United States for Patients with Breast CancerBy Nasdaq OMXMar 13, 2017, 11:05 AM UTC
BusinessETST & Cannabis Therapeutics Inc. Announce its Cannabis Cannabinoid-Based Nutraceutical Patent & Generic Pharmaceutical Drug Timeline & Update.By Nasdaq OMXMar 6, 2017, 12:45 PM UTC
BusinessEarth Science Tech Inc. and Cannabis Therapeutics Inc. to hold High-Level R&D Strategy Session in Laval, Qc and announces Dr. Moutih Rafei, PhD, as a new member of the Advisory BoardBy Nasdaq OMXFeb 28, 2017, 1:00 PM UTC
BusinessGeneSight® Psychotropic Test Demonstrated Substantial Cost Savings for Payers in New Study Published in Clinical TherapeuticsBy Nasdaq OMXFeb 23, 2017, 12:05 PM UTC
